- Home
- MYGN vs LILAK Comparison
MYGN vs LILAK Comparison
Compare MYGN & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- LILAK
- Stock Information
- Founded
- MYGN 1991
- LILAK 2017
- Country
- MYGN United States
- LILAK Bermuda
- Employees
- MYGN N/A
- LILAK N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- LILAK Cable & Other Pay Television Services
- Sector
- MYGN Health Care
- LILAK Telecommunications
- Exchange
- MYGN Nasdaq
- LILAK Nasdaq
- Market Cap
- MYGN 744.7M
- LILAK 1.1B
- IPO Year
- MYGN 1995
- LILAK N/A
- Fundamental
- Price
- MYGN $5.30
- LILAK $6.05
- Analyst Decision
- MYGN Hold
- LILAK Buy
- Analyst Count
- MYGN 15
- LILAK 3
- Target Price
- MYGN $15.14
- LILAK $10.27
- AVG Volume (30 Days)
- MYGN 1.9M
- LILAK 991.3K
- Earning Date
- MYGN 08-05-2025
- LILAK 08-05-2025
- Dividend Yield
- MYGN N/A
- LILAK N/A
- EPS Growth
- MYGN N/A
- LILAK N/A
- EPS
- MYGN N/A
- LILAK N/A
- Revenue
- MYGN $831,300,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- MYGN N/A
- LILAK $2.45
- Revenue Next Year
- MYGN $6.68
- LILAK $3.11
- P/E Ratio
- MYGN N/A
- LILAK N/A
- Revenue Growth
- MYGN 7.38
- LILAK N/A
- 52 Week Low
- MYGN $3.81
- LILAK $4.23
- 52 Week High
- MYGN $29.30
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- MYGN 55.01
- LILAK 64.18
- Support Level
- MYGN $4.90
- LILAK $5.78
- Resistance Level
- MYGN $5.29
- LILAK $6.09
- Average True Range (ATR)
- MYGN 0.25
- LILAK 0.22
- MACD
- MYGN 0.09
- LILAK 0.07
- Stochastic Oscillator
- MYGN 93.44
- LILAK 92.86
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.